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Clinical Trial Transparency — Antidote to Weaker
Off-Label-Promotion Rules?
Kevin Outterson, J.D., LL.M.

T

his year promises to be an auspicious period for
some long-running battles over the dissemination
of biomedical research. Some companies seeking more
freedom to promote their products have bristled at
recent guidance documents from
the Food and Drug Administration (FDA) regarding promotion of
drugs and devices for off-label
uses, claiming that they violate
the First Amendment. Simultaneously, industry is divided over calls
for increased transparency of clinical trial results. But as the FDA’s
regulatory authority is weakened
by First Amendment challenges,
the need for clinical trial transparency becomes more urgent.
In the recent guidance documents, the FDA recommended
that scientific articles used for offlabel promotion be scientifically
sound, come from peer-reviewed
journals, and be distributed in
unabridged form with the approved labeling and a comprehensive bibliography. Clinical prac-

tice guidelines used for marketing
should be based on a systematic
review of the evidence and “be
developed by a knowledgeable,
multidisciplinary panel of experts
and representatives from key affected groups.” The FDA also
recognized the growing importance of social media, describing
the situations in which a company is responsible for comments
on Facebook and patient-advocacy
websites focusing on specific diseases and treatments. In early
June, the FDA expanded this
guidance process to include communications about new risk data
for existing drugs. The FDA is
concerned that companies might
use incomplete new information
to weaken the impact of warnings on the approved drug label.
n engl j med 371;1
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Some companies have complained that these rules overly
constrain their marketing practices and impermissibly infringe
on commercial speech. These
claims find some support in recent cases that have undermined
the FDA’s regulatory authority
over drug marketing. The First
Amendment has emerged as a
potent deregulatory weapon for
corporations. Governments increasingly face First Amendment
challenges to rules related to the
marketing of regulated products,
not only from the drug industry
but also from companies selling
tobacco, alcohol, and processed
foods. These industries claim that
the government violates a core
principle of liberty — freedom of
speech — by regulating how
food, drugs, alcohol, and tobacco
are sold. The FDA issued the new
guidance documents with these
concerns in view.
In recent years, drug companies have paid billions of dollars
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in fines related to off-label promotion. Whether the First Amendment protects this activity remains an open question. The
FDA’s position is nuanced. Under
the law, a drug is viewed as
“mislabeled” unless “its labeling
bears adequate directions for use.”
The FDA does not require labels
to discuss all possible uses, which
would be burdensome to the companies, but only those actually intended by the company. One way
to prove this intention is to examine company statements about
the drug, including promotional
activity. Companies can make any
truthful and nonmisleading statement about their drugs, but when
they choose to speak about any
particular use, the label must
bear adequate directions for that
use. Speech is frequently used to
prove elements of other crimes;
examples include perjury, premeditated murder, and conspiracy.
Seen in this light, the recent
draft guidance documents do not
constrain First Amendment values. They provide safe harbors,
listing circumstances in which
the FDA will not consider actions
to be evidence of intent to sell a
drug for a particular use. And the
guidance is quite lenient: a company can sponsor biomedical research for an off-label use, refuse
to submit that research to the
FDA for an expanded label, but
nevertheless widely distribute reprints of relevant journal articles
to physicians and chat about them
on Facebook and other social
media. The FDA is keeping a respectful distance from the First
Amendment, while gently reinforcing better practices, including peer review and disclosure of
conflicts of interest.
If the Supreme Court’s interpretation of the First Amendment continues to constrain FDA
influence over the dissemination
2

of research, then even greater
importance must be placed on
improving research quality and
providing the support independent
research teams need to reanalyze
clinical trial data. Studies have
highlighted strategic weaknesses
in the research enterprise, including failures in peer review,
publication bias, bias introduced
by sponsors or investigators, and
extensive financial relationships.1
Transparency is an important
tool for addressing these issues,
and many stakeholders are working to improve transparency in
biomedical research. The International Committee of Medical
Journal Editors has adopted standards to improve the quality of
the peer-review process, require
registration of clinical trials before patient enrollment, and improve disclosure of conflicts of
interest. The United States requires advance registration of
many clinical trials; since 2007,
summary results must also be
published. Similar initiatives have
been implemented in Europe and
beyond, including a global clinical trial registry maintained by
the World Health Organization.
Advance registration and summary
publication are important tools
for reducing opportunities for
publication bias and making it
harder to hide negative studies.
Pressure is now building for
two additional data-transparency
goals: giving responsible independent researchers access to
patient-level data to enable them
to replicate studies and perform
meta-analyses2; and requiring public release of clinical study reports
submitted to governments for marketing approval, which have substantial informational value.3 Companies have traditionally protected
these data as trade secrets,4 but
major changes are under way.
In the United States, the FDA
n engl j med 371;1
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requested comments in 2013 on
a proposal supporting a limited
level of transparency for productmasked patient data. Product
masking protects the identity of
both the drug and the patient,
which limits the data’s clinical
utility for research. Currently,
this effort appears to be on hold,
awaiting results from a review by
the Institute of Medicine. Meanwhile, transparency initiatives by
some companies and legislative
action in Europe may have
reached the tipping point, with
momentum growing for transparency that goes well beyond
product-masked data.
Limited patient-level data are
now being made available to independent researchers. In May
2013, GlaxoSmithKline opened
some of its patient-level data to
responsible researchers, with an
independent review panel acting as
the gatekeeper.5 Johnson & Johnson followed suit in January 2014,
partnering with a group at Yale.
These programs are welcome improvements and should expand
across the industry.
I believe that transparency
should also extend to the clinical
study reports submitted to the
FDA and other drug-regulatory
authorities. On April 2, 2014, the
European Parliament adopted reforms to its rules governing human clinical trials, including a key
provision requiring delayed release
of clinical study reports submitted to the European Medicines
Agency. The next day, AbbVie
dropped its lawsuit against the
agency, which had sought the release of clinical study reports on
two AbbVie drugs. Other litigation remains pending, and the
European Union may yet weaken
these rules, but these events suggest that disclosure of clinical
study reports may soon be the
norm in Europe.
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In public comments on the
European reforms, the drug industry raised objections to the
release of clinical study reports.
Although companies have no
trade-secrecy right to hide safety
data on medicines, they make a
reasonable point re
An audio interview
with Professor
garding the danger
Outterson is
of substantial comavailable at NEJM.org
petitive harm from
full transparency. Governments
offer non–patent-based incentives
for special categories of drugs,
such as orphan drugs and biologics. These incentives have frequently rested on data exclusivity, prohibiting other companies from
using data for regulatory approval purposes. To the extent that
transparency disrupts data-exclusivity incentives and the timing
of generic entry, both domestically and internationally, the law
will need to be adjusted in order
to restore the competitive posi-

tion of the companies. The alternative is to delay data releases
until many years after a drug is
approved, but neither the progress of science nor public safety
should wait for full transparency.
The companies will also retain
the full force of patent law to
block premature generic entry. If
this issue is resolved, the onus
will be on the industry to articulate why clinical study reports
should not be immediately released when a drug is approved.
After decades of criticism
about bias in the clinical trial enterprise, new norms are being established that promote transparency. Additional transparency is
particularly welcome in the United
States, since the Supreme Court
has increasingly constrained the
FDA’s ability to regulate off-label
marketing activities. In the deregulatory environment fostered
by First Amendment challenges,

clinical trial transparency is perhaps the best remaining option
for informing physicians and
protecting patients.
Disclosure forms provided by the author
are available with the full text of this article
at NEJM.org.
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Putting Quality on the Global Health Agenda
Kirstin W. Scott, M.Phil., and Ashish K. Jha, M.D., M.P.H.

I

n 2005, after years of persistently high maternal mortality
rates, India implemented Janani
Suraksha Yojana (JSY), a conditional cash-transfer program in which
women were paid to deliver their
babies in health care institutions.
The program’s effect was as profound as it was disappointing: although the rates of institutional
deliveries soared, there was no
detectable effect on the country’s
maternal mortality rate.1
This paradox — a substantial
increase in access to health care
services with little improvement
in patient outcomes — holds a
critical lesson. Universal health
coverage has been proposed as a

potential umbrella goal for health
in the next round of global development priorities.2 The reasons
for focusing on such a goal are
compelling: for much of the
world’s population, access to
health care is severely limited
and often financially out of reach.
Policymakers have responded by
developing creative financing
plans, workforce training efforts,
and other programs that enhance
a country’s capacity to provide
health care services while ensuring financial protection for its
citizens. Though these efforts are
necessary, lessons from recent interventions that focus primarily
on enhancing access — such as
n engl j med 371;1
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JSY in India — remind us that
augmenting access will not be
enough. In order to improve the
health of the world’s population,
we need to simultaneously ensure that the care provided is of
sufficiently high quality, an issue that has garnered far less
concrete attention.
Although there is no single
definition of high-quality care, the
Institute of Medicine describes it
as having six key features: it is
safe, effective, patient-centered,
efficient, timely, and equitable.
All these features are important,
but there is recent evidence of
particularly substantial deficiencies in the first three (see table).
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